These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18762913)

  • 1. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Feb; 379(2):191-9. PubMed ID: 18762913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
    Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
    Someya Y; Nakano R; Tahara A; Takasu T; Takeuchi A; Nagase I; Matsuyama-Yokono A; Hayakawa M; Sasamata M; Miyata K; Uchiyama Y
    Eur J Pharmacol; 2009 Nov; 622(1-3):71-7. PubMed ID: 19766107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S; Sole S
    Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.
    Yeh KC; Yeh TK; Huang CY; Hu CB; Wang MH; Huang YW; Chou LH; Ho HH; Song JS; Hsu T; Jiaang WT; Chao YS; Chen CT
    Life Sci; 2021 Aug; 278():119574. PubMed ID: 33961850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
    Takayanagi R; Uchida T; Kimura K; Yamada Y
    Biopharm Drug Dispos; 2017 May; 38(4):273-279. PubMed ID: 27976813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
    Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
    [No Abstract]   [Full Text] [Related]  

  • 16. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
    Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
    Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.